Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress, for the 30-month mark of the ERIVANCE trial. The Congress is meeting November 13-16 in Zurich, Switzerland.
Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress for the 30-month mark of the ERIVANCE trial. The Congress is meeting November 13-16 in Zurich, Switzerland.
Vismodegib, marketed as Erivedge, is recommended for patients with advanced basal cell carcinoma (BCC) for whom surgery or radiation are no longer options. In the ERIVANCE trial, vismodegib, a Hedgehog pathway inhibitor, showed objective response rates (ORR) by an independent review of 30% in metastatic BCC and 43% in locally advanced BCC.
ORRs, by an investigator review, were 45% for metastatic BCC and 60% for locally advanced BCC, with a median duration of response of 12.9 and 7.6 months, respectively. Safety and efficacy results represent data at 30 months ending May 30, 2013, following primary analysis on November 26, 2010. At the start of the study, 104 patients had radiographically measurable metastatic BCC or locally advanced BCC (with surgery inappropriate due to multiple recurrence, or substantial morbidity or deformity foreseen). Patients received 150 mg of oral vismodegib once a day until disease progression or intolerable toxicity.
Secondary endpoints included ORR, DOR, progression-free survival (PFS), overall survival, and safety. The study examined subsets of patients to determine if there were different treatment effects. At the time of the data cutoff, 8 patients were receiving the study drug and undergoing protocol assessments, with 69 patients in survival follow-up. The overall response rate was 48.5% for metastatic BCC, and 60.3% for locally advanced BCC, with 20 complete responses and 18 partial responses. Median PFS was higher among the patients with locally advanced BCC than those with metastatic BCC. Overall survival for metastatic BCC was 33.4 months. Adverse events were consistent with those previously reported in the primary analysis, and 17 deaths—not considered drug-related—were reported since that time, during survival follow-up. Results confirm previously reported long-term safety of vismodegib for patients with advanced BCC.
Reference
Sekulic A., Migden M., Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): final update (30-month) of the pivotal ERIVANCE BCC study. Presented at Society for Melanoma Research, 2014 International Congress, November 13-16, 2014, Zurich, Switzerland.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More